Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: The EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial

Miller, 2011, Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association, Circulation, 123, 2292, 10.1161/CIR.0b013e3182160726 2002, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report, Circulation, 106, 3143, 10.1161/circ.106.25.3143 Davidson, 2012, A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova® compared to Lovaza® in a pharmacokinetic single-dose evaluation) study, J Clin Lipidol, 6, 573, 10.1016/j.jacl.2012.01.002 Lawson, 1988, Human absorption of fish oil fatty acids as triacylglycerols, free acids, or ethyl esters, Biochem Biophys Res Commun, 152, 328, 10.1016/S0006-291X(88)80718-6 Lawson, 1988, Absorption of eicosapentaenoic acid and docosahexaenoic acid from fish oil triacylglycerols or fish oil ethyl esters co-ingested with a high-fat meal, Biochem Biophys Res Commun, 156, 960, 10.1016/S0006-291X(88)80937-9 Ridker, 2012, Relationship of lipoprotein-associated phospholipase A2 mass and activity with incident vascular events among primary prevention of patients allocated to placebo or to statin therapy: an analysis from the JUPITER trial, Clin Chem, 58, 877, 10.1373/clinchem.2011.180281 Musa-Veloso, 2010, Long-chain omega-3 fatty acids eicosapentaenoic acid and docosahexaenoic acid dose-dependently reduce fasting serum triglycerides, Nutr Rev, 68, 155, 10.1111/j.1753-4887.2010.00272.x Offman, 2013, Steady-state bioavailability of prescription omega-3 on a low-fat diet is significantly improved with a free fatty acid formulation compared with an ethyl ester formulation: the ECLIPSE II study, Vasc Health Risk Manag, 9, 563, 10.2147/VHRM.S50464 Perk, 2012, Eur Heart J, 33, 1635, 10.1093/eurheartj/ehs092 Harris, 1997, Safety and efficacy of Omacor in severe hypertriglyceridemia, J Cardiovasc Risk, 4, 385, 10.1097/00043798-199710000-00011 Abe, 1998, Soluble cell adhesion molecules in hypertriglyceridemia and potential significance on monocyte adhesion, Arterioscler Thromb Vasc Biol, 18, 723, 10.1161/01.ATV.18.5.723 Nordøy, 1998, Effects of simvastatin and omega-3 fatty acids on plasma lipoproteins and lipid peroxidation in patients with combined hyperlipidaemia, J Intern Med, 243, 163, 10.1046/j.1365-2796.1998.00297.x Pownall, 1999, Correlation of serum triglyceride and its reduction by omega-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins, Atherosclerosis, 143, 285, 10.1016/S0021-9150(98)00301-3 Stalenhoef, 2000, The effect of concentrated n-3 fatty acids versus gemfibrozil on plasma lipoproteins, low density lipoprotein heterogeneity and oxidizability in patients with hypertriglyceridemia, Atherosclerosis, 153, 129, 10.1016/S0021-9150(00)00381-6 Westphal, 2000, Postprandial chylomicrons and VLDLs in severe hypertriacylglycerolemia are lowered more effectively than are chylomicron remnants after treatment with n-3 fatty acids, Am J Clin Nutr, 71, 914, 10.1093/ajcn/71.4.914 Durrington, 2001, An omega-3 polyunsaturated fatty acid concentrate administered for one year decreased triglycerides in simvastatin and treated patients with coronary heart disease and persisting hypertriglyceridaemia, Heart, 85, 544, 10.1136/heart.85.5.544 Chan, 2003, Randomized controlled trial of the effect of n-3 fatty acid supplementation on the metabolism of apolipoprotein B-100 and chylomicrons remnants in men with visceral obesity, Am J Clin Nutr, 77, 300, 10.1093/ajcn/77.2.300 Davidson, 2007, Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study, Clin Ther, 29, 1354, 10.1016/j.clinthera.2007.07.018 Maki, 2008, Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia, Am J Cardiol, 102, 429, 10.1016/j.amjcard.2008.03.078 Maki, 2011, Effects of prescription omega-3-acid ethyl esters on fasting lipid profile in subjects with primary hypercholesterolemia, J Cardiovasc Pharmacol, 57, 489, 10.1097/FJC.0b013e318210fca5 Maki, 2011, Prescription omega-3-acid ethyl esters reduce fasting and postprandial triglycerides and modestly reduce pancreatic β-cell response in subjects with primary hypertriglyceridemia, Prostaglandins Leukot Essent Fatty Acids, 85, 143, 10.1016/j.plefa.2011.06.005 Bays, 2010, Effects of prescription omega-3-acid ethyl esters on non-high-density lipoprotein cholesterol when coadministered with escalating doses of atorvastatin, Mayo Clin Proc, 85, 122, 10.4065/mcp.2009.0397 Ballantyne, 2012, Efficacy and safety of eicosapentaenoic acid ethyl ester (AMR101) therapy in statin-treated patients with persistent high triglycerides (from the ANCHOR study), Am J Cardiol, 119, 984, 10.1016/j.amjcard.2012.05.031 Signori, 2012, Administration of omega-3 fatty acids and raloxifene to women at high risk of breast cancer: interim feasibility and biomarkers analysis from a clinical trial, Eur J Clin Nutr, 66, 878, 10.1038/ejcn.2012.60 Tatsuno, 2013, Efficacy and safety of TAK-085 compared with eicosapentaenoic acid in Japanese subjects with hypertriglyceridemia undergoing lifestyle modification: the omega-3 fatty acids randomized double-blind (ORD) study, J Clin Lipidol, 7, 199, 10.1016/j.jacl.2013.01.006 Bays, 2011, Eicosapentaenoic acid ethyl ester (AMR101) therapy in patients with very high triglyceride levels (from the Multi-center, plAcebo-controlled, Randomized, double-blInd, 12-week study with an open-label Extension [MARINE] trial), Am J Cardiol, 108, 682, 10.1016/j.amjcard.2011.04.015 Harris, 1997, n-3 Fatty acids and serum lipoproteins: human studies, Am J Clin Nutr, 65, 1645S, 10.1093/ajcn/65.5.1645S Harris, 1997, Influence of n-3 fatty acid supplementation on the endogenous activities of plasma lipases, Am J Clin Nutr, 66, 254, 10.1093/ajcn/66.2.254 McKenney, 2007, Prescription omega-3 fatty acids for the treatment of hypertriglyceridemia, Am J Health Syst Pharm, 64, 595, 10.2146/ajhp060164 Harris, 2008, Omega-3 fatty acids and coronary heart disease risk: clinical and mechanistic perspectives, Atherosclerosis, 197, 12, 10.1016/j.atherosclerosis.2007.11.008 Tan, 1995, Relations between plasma lipids and postheparin plasma lipases and VLDL and LDL subfraction patterns in normolipemic men and women, Arterioscler Thromb Vasc Biol, 15, 1839, 10.1161/01.ATV.15.11.1839 Demant, 1998, In vivo studies of VLDL metabolism and LDL heterogeneity, Eur Heart J, 19, H7 Sniderman, 2012, Phenotypes of hypertriglyceridemia caused by excess very-low-density lipoprotein, J Clin Lipidol, 6, 427, 10.1016/j.jacl.2012.04.081 Davidson, 2009, Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia, J Clin Lipidol, 5, 332, 10.1016/j.jacl.2009.08.001 Maki, 2011, Effects of prescription omega-3-acid ethyl esters, coadministered with atorvastatin, on circulating levels of lipoprotein particles, apolipoprotein CIII and lipoprotein-associated phospholipase A2 mass in men and women with mixed dyslipidemia, J Clin Lipidol, 5, 483, 10.1016/j.jacl.2011.09.001 Robinson, 2009, Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk, J Am Coll Cardiol, 53, 316, 10.1016/j.jacc.2008.10.024 Di Angelantonio, 2012, Lipid-related markers and cardiovascular disease prediction, JAMA, 307, 2499 Boekholdt, 2012, Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis, JAMA, 307, 1302, 10.1001/jama.2012.366 Sondermeijer, 2013, Non-HDL cholesterol vs. Apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study, Eur J Clin Invest, 43, 1009, 10.1111/eci.12129 Yahagi, 1999, A crucial role of sterol regulatory element-binding protein-1 in the regulation of lipogenic gene expression by polyunsaturated fatty acids, J Biol Chem, 274, 35840, 10.1074/jbc.274.50.35840 Chan, 2002, Regulatory effects of HMG CoA reductase inhibitors and fish oils on Apo B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia, Diabetes, 51, 2377, 10.2337/diabetes.51.8.2377 Khan, 2002, Dietary long-chain n-3 PUFAs increase LDL gene expression in adipose tissue of subjects with an atherogenic lipoprotein phenotype, J Lipid Res, 43, 979, 10.1016/S0022-2275(20)30473-9 Park, 2003, Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance, J Lipid Res, 44, 455, 10.1194/jlr.M200282-JLR200 Jump, 2005, Fatty acid regulation of hepatic gene transcription, J Nutr, 135, 2503, 10.1093/jn/135.11.2503 Davidson, 2006, Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids, Am J Cardiol, 98, 27i, 10.1016/j.amjcard.2005.12.024 Harris, 2006, Why do omega-3 fatty acids lower serum triglycerides?, Curr Opin Lipidol, 17, 387, 10.1097/01.mol.0000236363.63840.16 Kawakami, 2009, Apolipoprotein CIII links dyslipidemia with atherosclerosis, J Atheroscler Thromb, 16, 6, 10.5551/jat.E607 Olivieri, 2005, Apolipoprotein C-III, n-3 polyunsaturated fatty acids, and “insulin-resistant” T-455C APOC3 gene polymorphism in heart disease patients: example of gene-diet interaction, Clin Chem, 51, 360, 10.1373/clinchem.2004.040477 Sacks, 2000, VLDL, apolipoproteins B, CIII, and E, and risk of recurrent coronary events in the Cholesterol and Recurrent Events (CARE) trial, Circulation, 102, 1886, 10.1161/01.CIR.102.16.1886 Barzilai, 2003, Unique lipoprotein phenotype and genotype associated with exceptional longevity, JAMA, 290, 2030, 10.1001/jama.290.15.2030 Pollin, 2008, A null mutation in human APOC3 confers a favorable plasma lipid profile and apparent cardioprotection, Science, 322, 1702, 10.1126/science.1161524 Anderson, 2008, Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention, Am J Cardiol, 101, 23F, 10.1016/j.amjcard.2008.04.015 Toth, 2010, Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker, Exp Rev Cardiovasc Ther, 8, 425, 10.1586/erc.10.18 Davidson, 2011, Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists, J Clin Lipidol, 5, 338, 10.1016/j.jacl.2011.07.005 Bays, 2013, Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies, Am J Cardiovasc Drugs, 13, 37, 10.1007/s40256-012-0002-3 Nakamura, 2004, Structure, function, and dietary regulation of 6, 5, and 9 desaturases, Annu Rev Nutr, 24, 345, 10.1146/annurev.nutr.24.121803.063211 Raatz, 2012, Total dietary fat and fatty acid content modifies plasma phospholipid fatty acids, desaturate activity indices, and urinary prostaglandin E in women, Nutr Res, 32, 1, 10.1016/j.nutres.2011.12.006 Saito, 2012, The mechanisms mediating the effect of n-3 fatty acids on triglyceride (TG) biosynthesis in rats, Prostaglandins Leukot Essent Fatty Acids, 86, 209, 10.1016/j.plefa.2012.03.005 DeCaterina, 1990, Vascular prostacyclins is increased in patients ingesting omega-3 polyunsaturated fatty acids before coronary artery bypass graft surgery, Circulation, 82, 428, 10.1161/01.CIR.82.2.428 Patel, 2010, Omega-3 polyunsaturated acids and cardiovascular disease: notable ethnic differences of unfulfilled promise?, J Thromb Haemost, 8, 2095, 10.1111/j.1538-7836.2010.03956.x